On January 09, 2026, this newsletter featured 5 insider purchases detected from SEC Form 4 filings.
📈 Daily Insider & Cluster Buy Highlights – January 09, 2026
Here are some of the most interesting insider and cluster buying signals from the last 7 days.
⚠️ For information purposes only.
This information is provided for informational purposes only and does not constitute investment advice, financial advice, trading advice, or any other type of advice. All investments carry risk, including the potential loss of principal. Past performance is not indicative of future results. You should consult with a qualified financial advisor, accountant, or other professional before making any investment decisions. The information contained in this newsletter is not intended to be a substitute for professional financial advice.
📊 About Fair Value:
The Fair Value shown for each company is calculated using a Levered Discounted Cash Flow (DCF) model. This method estimates the intrinsic value of a stock by projecting future cash flows and discounting them back to present value, accounting for the company's debt structure. A positive percentage difference indicates the stock may be undervalued relative to this model, while a negative percentage suggests it may be overvalued. Fair value calculations are estimates and should be considered alongside other factors.
🔥 Notable Cluster Buys (≥ $500,000)
No new qualifying cluster buys in the last 7 days.
💼 Notable Individual Insider Buys (≥ $100,000)
10% Owner
Zentalis Pharmaceuticals, Inc ($ZNTL)
Transaction Date: Dec 31, 2025
Shares: 6,459,973
Purchase Price: $1.20
Purchase Value: $7,751,968
📈
P&L: 136.7% ($10,594,356 gain)
📊 Valuation & Analyst Info:
Fair Value: $6.10 (114.8% undervalued vs current price)
Analyst Rating: B
Avg Price Target: $2.00 (-29.6% vs current)
📰 Recent News (Last 7 Days):
GlobeNewsWire • Jan 06, 2026
Completed enrollment in DENALI Part 2a; dose confirmation expected in 1H 2026 DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approval Initiation of the...
BROADWOOD PARTNERS, L.P.View Chart
10% Owner
STAAR SURGICAL CO ($STAA)
Transaction Date: Jan 06, 2026
Shares: 186,946
Purchase Price: $21.01
Purchase Value: $3,927,941
📈
P&L: 7.1% ($278,344 gain)
📊 Valuation & Analyst Info:
Fair Value: $15.63 (30.5% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $29.83 (+32.6% vs current)
📰 Recent News (Last 7 Days):
Business Wire • Jan 06, 2026
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
Benzinga • Jan 06, 2026
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of St...
Business Wire • Jan 06, 2026
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Business Wire • Jan 06, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
BROADWOOD PARTNERS, L.P.View Chart
10% Owner
STAAR SURGICAL CO ($STAA)
Transaction Date: Jan 06, 2026
Shares: 150,000
Purchase Price: $22.38
Purchase Value: $3,356,340
📈
P&L: 0.6% ($18,660 gain)
📊 Valuation & Analyst Info:
Fair Value: $15.63 (30.5% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $29.83 (+32.6% vs current)
📰 Recent News (Last 7 Days):
Business Wire • Jan 06, 2026
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
Benzinga • Jan 06, 2026
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of St...
Business Wire • Jan 06, 2026
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Business Wire • Jan 06, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
BROADWOOD PARTNERS, L.P.View Chart
10% Owner
STAAR SURGICAL CO ($STAA)
Transaction Date: Jan 07, 2026
Shares: 66,467
Purchase Price: $22.00
Purchase Value: $1,462,301
📈
P&L: 2.3% ($33,207 gain)
📊 Valuation & Analyst Info:
Fair Value: $15.63 (30.5% overvalued vs current price)
Analyst Rating: C+
Avg Price Target: $29.83 (+32.6% vs current)
📰 Recent News (Last 7 Days):
Business Wire • Jan 06, 2026
GENEVA--(BUSINESS WIRE)--Alcon Terminates Agreement to Acquire STAAR Surgical.
Benzinga • Jan 06, 2026
STAAR Surgical Company (NASDAQ: STAA) announced Tuesday that it did not receive the necessary stockholder votes to approve the merger agreement with Alcon Inc. (NYSE: ALC) at the Special Meeting of St...
Business Wire • Jan 06, 2026
NEW YORK--(BUSINESS WIRE)--Broadwood Partners, L.P. and its affiliates (“Broadwood” or “we”), which together own 30.2% of the outstanding common stock of STAAR Surgical Company (“STAAR” or the “Compan...
Business Wire • Jan 06, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correc...
10% Owner
GRAN TIERRA ENERGY INC ($GTE)
Transaction Date: Jan 05, 2026
Shares: 100,000
Purchase Price: $4.04
Purchase Value: $404,050
📈
P&L: 6.2% ($24,950 gain)
📊 Valuation & Analyst Info:
Fair Value: $111.47 (2498.5% undervalued vs current price)
Analyst Rating: C+
📰 Recent News (Last 7 Days):
Defense World • Jan 02, 2026
Gran Tierra Energy (NYSE: GTE - Get Free Report) and Sanchez Energy (OTCMKTS:SNEC - Get Free Report) are both small-cap energy companies, but which is the superior investment? We will contrast the two...
This newsletter is generated automatically. Please verify all information independently before making investment decisions.